Fresenius Unveils Ambitious Turnaround Plan Amid Solid Financials

Fresenius targets 7% organic sales growth and an 11.5% EBIT margin, aiming to lift its share price sustainably above key technical levels.

Fresenius has formally initiated a significant strategic pivot aimed at accelerating value creation. Dubbed the "Rejuvenate" phase, this move signals management's intent to leave a period of restructuring behind and shift the company into a higher gear. The foundation for this ambitious plan appears solid, as evidenced by the recently published financial targets for the 2025 fiscal year.

A Confident Outlook for 2026

Guided by its new strategic direction, the company's leadership is targeting continued profitable growth for the current year. Their forecast includes an organic sales increase of up to 7%, alongside an expected EBIT margin of approximately 11.5%. This margin target now stands as a key benchmark for management's performance, with the overarching goal of sustainably lifting the share price above its 200-day moving average of €47.04.

The "Rejuvenate" strategy is central to this effort, focusing on streamlining operational processes and bolstering profitability for the long term. For investors, the next critical milestone will be the equity's ability to break through technical resistance levels. Currently, the stock remains roughly 15% below its 52-week high of €52.10.

Financial Performance Provides a Springboard

The company's latest annual results offer a robust platform for its renewed ambitions. Group revenue saw organic growth of 7%, reaching €22.55 billion. Operational performance also strengthened, with EBIT (earnings before interest and taxes) advancing to nearly €2.6 billion.

A primary source of the board's confidence is the currency-adjusted core earnings per share, which jumped 12% to €2.87. This metric suggests that prior efficiency measures are yielding results. However, this operational progress has not yet been fully reflected in the share price. Closing at €44.45 on Wednesday, the stock continues to trade about 8% below its 50-day moving average of €48.41.